Comparison of vascular response between durable and biodegradable polymerbased drug-eluting stents in a porcine coronary artery model

EuroIntervention

Volumn 10, Issue 6, 2014, Pages 717-723

  Nakazawa, Gaku ^a   Shinke, Toshiro ^b   Ijichi, Takeshi ^a   Matsumoto, Daisuke ^b   Otake, Hiromasa ^b   Torii, Sho ^a   Hiranuma, Noritoshi ^b   Ohsue, Tsuyoshi ^b   Otsuka, Fumiyuki ^c   Shite, Junya ^b   Hirata, Ken Ichi ^b   Ikari, Yuji ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CVPATH INSTITUTE   (United States)

Author keywords

Biocompatibility; Biodegradable polymer; Drug eluting stents

Indexed keywords

ACETYLCHOLINE; EVEROLIMUS; POLYMER; RAPAMYCIN; BIOMATERIAL; UMIROLIMUS; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; BIODEGRADABLE IMPLANT; BLOOD VESSEL REACTIVITY; COMPOSITE MATERIAL; CONTROLLED STUDY; CORONARY STENT; CORONARY STENTING; DRUG ELUTING STENT; EQUIPMENT DESIGN; FOLLOW UP; GIANT CELL; GRANULOMATOUS INFLAMMATION; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LONG TERM CARE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; PORCINE MODEL; PROSTHESIS MATERIAL; PROVOCATION TEST; VASCULITIS; VASOCONSTRICTION; ANALOGS AND DERIVATIVES; ANGIOCARDIOGRAPHY; ANIMAL; COMPARATIVE STUDY; CORONARY BLOOD VESSEL; INFLAMMATION; MATERIALS TESTING; NEOINTIMA; PATHOLOGY; PIG;

ABSORBABLE IMPLANTS; ACETYLCHOLINE; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY VESSELS; DRUG-ELUTING STENTS; INFLAMMATION; MATERIALS TESTING; MODELS, ANIMAL; NEOINTIMA; POLYMERS; SIROLIMUS; SWINE; TOMOGRAPHY, OPTICAL COHERENCE; VASODILATOR AGENTS;

EID: 84908304023     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV10I6A124     Document Type: Article

References (30)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R: RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-80.
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23.
3. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-21.
4. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-91.
5. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440-55.
6. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
7. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138-45.
8. Palmerini T, Biondi-Zoccai G, Riva DD, Mariani A, Savini C, Di Eusanio M, Genereux P, Frati G, Marullo AG, Landoni G, Greco T, Branzi A, De Servi S, Di Credico G, Taglieri N, Williams MR, Stone GW. Risk of stroke with percutaneous coronary intervention compared with on-pump and off-pump coronary artery bypass graft surgery: evidence from a comprehensive network meta-analysis. Am Heart J. 2013;165:910-7.
9. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314-22.
10. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-5.
11. Nakazawa G, Finn AV, Ladich E, Ribichini F, Coleman L, Kolodgie FD, Virmani R. Drug-eluting stent safety: findings from preclinical studies. Expert Rev Cardiovasc Ther. 2008;6:1379-91.
12. Virmani R, Kolodgie FD, Farb A, Lafont A. Drug eluting stents: are human and animal studies comparable? Heart. 2003;89:133-8.
13. Nakamura T, Brott BC, Brants I, Panchal D, Li J, Chen JP, King SB 3rd, Chronos N, Hou D. Vasomotor function after paclitaxel-coated balloon post-dilation in porcine coronary stent model. JACC Cardiovasc Interv. 2011;4:247-55.
14. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-74.
15. Granada JF, Inami S, Aboodi MS, Tellez A, Milewski K, Wallace-Bradley D, Parker S, Rowland S, Nakazawa G, Vorpahl M, Kolodgie FD, Kaluza GL, Leon MB, Virmani R. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ Cardiovasc Interv. 2010;3:257-66.
16. Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis. 2004;15:313-8.
17. Fujii K, Kawasaki D, Oka K, Akahori H, Fukunaga M, Sawada H, Masutani M, Lee-Kawabata M, Tsujino T, Ohyanagi M, Masuyama T. Endothelium-dependent coronary vasomotor response and neointimal coverage of zotarolimus-eluting stents 3 months after implantation. Heart. 2011;97:977-82.
18. Shinke T, Li J, Chen JP, Pendyala L, Goodchild T, Jabara R, Geva S, Ueno T, Chronos N, Robinson K, Hou D. High incidence of intramural thrombus after overlapping paclitaxel-eluting stent implantation: angioscopic and histopathologic analysis in porcine coronary arteries. Circ Cardiovasc Interv. 2008;1:28-35.
19. Takano M, Murakami D, Yamamoto M, Kurihara O, Murai K, Inami T, Kimata N, Ohba T, Seino Y, Mizuno K. Six-month follow-up evaluation for everolimus-eluting stents by intracoronary optical coherence tomography: comparison with paclitaxel-eluting stents. Int J Cardiol. 2013;166:181-6.
20. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-42.
21. Guagliumi G, Sirbu V. Optical coherence tomography: high resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv. 2008;72:237-47.
22. Nakazawa G, Finn AV, Kolodgie FD, Virmani R. A review of current devices and a look at new technology: drug-eluting stents. Expert Rev Med Devices. 2009;6:33-42.
23. Pendyala LK, Matsumoto D, Shinke T, Iwasaki T, Sugimoto R, Hou D, Chen JP, Singh J, King SB 3rd, Chronos N, Li J. Nobori stent shows less vascular inflammation and early recovery of endothelial function compared with Cypher stent. JACC Cardiovasc Interv. 2012;5:436-44.
24. Kolandaivelu K, Swaminathan R, Gibson WJ, Kolachalama VB, Nguyen-Ehrenreich KL, Giddings VL, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400-9.
25. Ostojic M, Sagic D, Jung R, Zhang YL, Nedeljkovic M, Mangovski L, Stojkovic S, Debeljacki D, Colic M, Beleslin B, Milosavljevic B, Orlic D, Topic D, Karanovic N, Paunovic D, Christians U; NOBORI PK Investigators. The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study. Catheter Cardiovasc Interv. 2008;72:901-8.
26. Imai M, Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, Hosogi S, Hirono A, Tanaka H, Tada T, Morimoto T, Shiomi H, Kozuma K, Inoue K, Suzuki N, Kimura T, Mitsudo K. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation. 2011;123:2382-91.
27. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabate M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-402.
28. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S. Improved safety and reduction in stent thrombosis associated with biodegradable polymerbased biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6:777-89.
29. Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B, Windecker S, Jüni P. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimuseluting stents in patients with coronary artery disease (LEADERS: 4 year follow-up of a randomised non-inferiority trial. Lancet. 2011;378:1940-8.
30. Smits PC, Hofma S, Togni M, Vazquez N, Valdes M, Voudris V, Slagboom T, Goy JJ, Vuillomenet A, Serra A, Nouche RT, den Heijer P, van der Ent M. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet. 2013;381:651-60.